Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 11/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12329283 | 0.90 | ADAM17 (0.59) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL13851576 | 0.89 | ADAM17 (0.55) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL4138479 | 0.83 | ADAM17 (0.54) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL7904577 | 0.81 | ADAM17 (0.64) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL863136 | 0.79 | NPC1 (0.66) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL4140361 | 0.78 | ADAM17 (0.58) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL9208913 | 0.78 | ADAM17 (0.61) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL4161376 | 0.77 | ADAM17 (0.51) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 | |
| SCHEMBL4149806 | 0.77 | POLB (0.64) | NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL5251770 | 0.76 | NPC1 (0.62) | ADAM17NPC1RAB9ASMN1; SMN2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| EP-1951244-A2 | CALCILYTIC COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007062370-A2 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137557-A1 | Calcilytic Compounds | CALCR, SOST, CALCB | ADAM17 649/4885NPC1 503/4885RAB9A 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.